Swk Hldgs Corp - SWKH STOCK NEWS

SWK Holdings (NASDAQ:SWKH) has announced the monetization of its royalty portfolio through two significant transactions. ANI Pharmaceuticals exercised its Iluvien royalty buyout option on March 17, 2025, resulting in a $17.3 million payment to SWK. Additionally, SWK has entered into an agreement with Soleus Capital to sell its remaining performing royalty portfolio for approximately $34.0 million in cash.

The combined monetization value of approximately $51.3 million represents a gain of $1.0 million over the portfolio's book value of $50.3 million as of December 31, 2024. The Soleus transaction is expected to close in two weeks, subject to customary conditions. SWK plans to declare a dividend to shareholders following the Soleus transaction closing, with the amount and record date to be announced at that time.

SWK Holdings (NASDAQ:SWKH) reported strong financial results for Q4 2024, with GAAP net income reaching $5.9 million ($0.48 per diluted share), up from $2.8 million in Q4 2023. Total revenue increased 25% to $12.4 million.

Key financial metrics include:

• Finance receivables segment revenue up 11.6% to $10.3 million
• Net finance receivables of $277.8 million, up 1.2% year-over-year
• Effective yield increased to 15.5%, up 150 basis points
• GAAP book value per share rose 5% to $23.45
• Non-GAAP tangible financing book value per share increased 8.3% to $21.15

The company monetized its performing royalty portfolio for approximately $51.3 million and plans to declare a dividend upon closing the final transaction. Portfolio improvements include successful workout conclusions and new financing agreements, including a $15 million commitment with Impedimed and an expanded $30 million credit facility with Eton.

SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company serving small- and mid-sized commercial-stage companies, has scheduled its fourth quarter and full year 2024 financial results announcement. The earnings release will be issued after market close on Wednesday, March 19, 2025.

The company will host a conference call to discuss its corporate and financial results on Thursday, March 20, 2025 at 10:00am ET. Investors can join via phone using the dial-in numbers (888)-506-0062 for domestic or (973)-528-0011 for international calls, with participant code 698628. A live webcast will also be available, and a replay will be accessible on the SWK Holdings website after the call.

ImpediMed has secured a five-year $15 million growth capital facility from SWK Holdings (NASDAQ:SWKH) to support its commercialization efforts. The company's SOZO® Digital Health Platform, the only FDA-cleared bioimpedance spectroscopy (BIS) technology for breast cancer-related lymphedema (BCRL) assessment, currently has U.S. health payor coverage for over 258 million lives.

The funding strengthens ImpediMed's capital base for executing its commercial strategy. In 2024, the National Accreditation Program for Breast Centers (NABPC) updated its standards to include lymphedema prevention programs using BIS, validating the technology's importance in lymphedema management and creating expansion opportunities for SOZO across breast cancer centers nationwide.

SWK Holdings (NASDAQ:SWKH) has provided a comprehensive portfolio update highlighting significant transactions from Q4 2024. The company made several new originations, including a $5.0M advance to Journey Medical, $0.6M to Biotricity (with 600,000 warrants), an $8.0M senior secured loan to Triple Ring Technologies, $2.5M to SKNV, a $25.7M facility expansion with Eton (with 289,736 warrants), and $2.5M to MedMinder.

On the repayments side, SWK received $4.1M from Exeevo's asset sale, $13.0M from Biolase's bankruptcy estate, $1.9M from Trio Healthcare, $4.2M from Veru's FC2 Female Condom sale, and $12.2M final payment from Moleculight. Additional payments are expected in 2025 from various sources, including Exeevo earn-outs and the Biolase estate.

SWK Holdings (SWKH) reported Q3 2024 financial results with GAAP net income of $3.5 million, down from $4.5 million in Q3 2023. Total revenue increased 15.6% to $10.4 million. Net finance receivables grew 14.4% to $255.9 million compared to the previous year. The company's effective yield was 14.6%, up 60 basis points from Q3 2023. Book value per share increased 3.7% to $22.94. The company repurchased approximately 340,000 shares for $5.8 million year-to-date through November 8, 2024. SWK closed new financing deals, including an $11.0 million royalty financing with Relief Therapeutics and a $25.7 million commitment to Eton Pharmaceuticals.

SWK Holdings (NASDAQ:SWKH) reported its Q2 2024 financial results. Key highlights include:

- GAAP net income of $4.4 million, up from $3.9 million in Q2 2023
- Finance receivables segment adjusted non-GAAP net income of $6.5 million, down from $7.6 million in Q2 2023
- Net finance receivables increased 19.0% to $265.5 million
- Effective yield of 14.6%, a 10 bps increase from Q2 2023
- Non-GAAP tangible financing book value per share rose 6.3% to $20.17

The company saw a 21.1% increase in total revenue to $11.5 million. However, it also recorded a $4.1 million provision for credit losses due to impairments on two non-accrual loans. SWK closed an $11 million royalty financing with Relief Therapeutics in August 2024.

SWK Holdings (Nasdaq: SWKH) has appointed Adam C. Rice, CPA, as Chief Financial Officer and promoted Courtney Baker, CPA, to Controller. Rice has over 18 years of experience in finance and accounting, previously serving as CFO of Park Cities Asset Management. His background includes roles in financial operations management, corporate financial planning, and strategic planning. Baker, who joined SWK Holdings in July 2023, has expertise in revenue recognition, SEC reporting, and M&A activity. Both executives are CPAs registered in Texas, strengthening SWK's leadership team in finance and accounting.

SWK Holdings (NASDAQ: SWKH) announced its financial results for Q1 2024. The company reported a GAAP net income of $0.9 million, down from $4.6 million in Q1 2023. Adjusted non-GAAP net income for the finance receivables segment was $2.7 million, compared to $7.3 million in the same quarter last year.

As of March 31, 2024, gross finance receivables were $274.5 million, a 10.3% increase year-over-year, with an effective yield of 14.2%. Despite a $6.0 million impairment to its loan book, the company saw a 23.7% revenue increase in its finance segment to $11.5 million.

The book value per share stood at $22.46, while the non-GAAP tangible financing book value per share was $19.69. During the quarter, SWK repurchased 58,298 shares of common stock for approximately $1 million.

SWK's Enteris division signed an Option and Asset Purchase Agreement and received a low-single-digit million-dollar option fee in April 2024. The company remains focused on high-margin, strategic opportunities in the life sciences finance market.